A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of this study is to test any good and bad effects of the study drug called SY-1425 (tamiboratene) in patients with acute myeloid leukemia (AML) who have a certain biomarker in their blood (a blood test may indicate the drug target is present in your type of AML).
Acute Myeloid Leukemia (AML)
-At least 18 years of age
-You have newly diagnosed AML
18 - n/a
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug for as long as you are tolerating it and your leukemia has not gotten worse. After you finish receiving the study drug, the investigator will continue to watch you for side effects and follow your condition 30 days after your last dose of study drug and then every 3 months for up to 2 years for survival.
Clinical Trials Information Line
Syros Pharmaceuticals, Inc.